- Home
- Publications
- Publication Search
- Publication Details
Title
Novel Immunotherapeutic Strategies of Gastric Cancer Treatment
Authors
Keywords
-
Journal
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
Volume 2011, Issue -, Pages 1-17
Publisher
Hindawi Limited
Online
2011-12-28
DOI
10.1155/2011/437348
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cytokine Induced Killer Cells as Promising Immunotherapy for Solid Tumors
- (2012) Dario Sangiolo Journal of Cancer
- A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer
- (2011) F De Vita et al. BRITISH JOURNAL OF CANCER
- Blocking the immunosuppressive axis with small interfering RNA targeting interleukin (IL)-10 receptor enhances dendritic cell-based vaccine potency
- (2011) J. H. Kim et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Cetuximab in Combination With Chemoradiotherapy Before Surgery in Patients With Resectable, Locally Advanced Esophageal Carcinoma: A Prospective, Multicenter Phase IB/II Trial (SAKK 75/06)
- (2011) Thomas Ruhstaller et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers
- (2010) B. F. El-Rayes et al. ANNALS OF ONCOLOGY
- Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study
- (2010) M. Moehler et al. ANNALS OF ONCOLOGY
- Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells
- (2010) Yeon Jin Kim et al. ARCHIVES OF PHARMACAL RESEARCH
- Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial
- (2010) N C Tebbutt et al. BRITISH JOURNAL OF CANCER
- Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
- (2010) F Lordick et al. BRITISH JOURNAL OF CANCER
- Enhancement of DC vaccine potency by activating the PI3K/AKT pathway with a small interfering RNA targeting PTEN
- (2010) Jin Hee Kim et al. IMMUNOLOGY LETTERS
- Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil With Bevacizumab in Patients With Metastatic Gastroesophageal Adenocarcinoma
- (2010) Manish A. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity
- (2010) Caroline J Voskens et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Cetuximab as Second-Line Therapy in Patients with Metastatic Esophageal Adenocarcinoma: A Phase II Southwest Oncology Group Study (S0415)
- (2010) Philip J. Gold et al. Journal of Thoracic Oncology
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer
- (2009) P. C. Enzinger et al. ANNALS OF ONCOLOGY
- Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie
- (2009) S. Lorenzen et al. ANNALS OF ONCOLOGY
- Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)
- (2009) C Pinto et al. BRITISH JOURNAL OF CANCER
- Characterization of tumor antigen peptide-specific T cells isolated from the neoplastic tissue of patients with gastric adenocarcinoma
- (2009) Amedeo Amedei et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- American Society of Clinical Oncology Provisional Clinical Opinion: Testing forKRASGene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
- (2009) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular basis of therapeutic approaches to gastric cancer
- (2009) Kaichun Wu et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer
- (2008) S Rao et al. BRITISH JOURNAL OF CANCER
- Immunotherapy for gastrointestinal cancer: current status and strategies for improving efficacy
- (2008) Eyad Elkord et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Cetuximab With Concurrent Chemoradiation for Esophagogastric Cancer: Assessment of Toxicity
- (2008) Howard Safran et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781
- (2008) Joel Tepper et al. JOURNAL OF CLINICAL ONCOLOGY
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- Understanding PTEN regulation: PIP2, polarity and protein stability
- (2008) N R Leslie et al. ONCOGENE
- Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma
- (2007) Markéta Tomšová et al. GYNECOLOGIC ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started